International ingredients specialist Prinova Europe has entered into a partnership with Norway-based Hofseth BioCare (HBC) to distribute its marine nutrition products in the EU.
HBC offers a wide range of protein, calcium and oil products from Norwegian salmon. It uses proprietary hydrolysis technology to extract nutrients from the fish sustainably, turning offcuts into high-value nutrition products with minimal waste.
Tony Gay, head of technical sales & NPD at Prinova Europe, said: “We’re very excited to have the opportunity to represent Hofseth BioCare in the European market. They’re a pioneer in the marine ingredients market, combining high quality with a commitment to innovation, sustainability and traceability. At a time of increasing interest in ethically produced marine ingredients, their range is perfectly in line with consumer trends.”
In HBC’s proprietary process, enzymes hydrolyse protein from the fish into peptides, leaving the oil and bones untouched. The peptides are then separated off into unprocessed natural fish oil (OmeGo) and natural marine collagen and calcium (CalGo).
Roger Hofseth, CEO of Hofseth BioCare, said: “Our unique technology makes it possible for us to create products using the whole fish, with zero waste. All our processes are focused on sustainability. We also offer total traceability – we can track our production process all the way from fish eggs to final products. There are many applications for our products in nutrition markets, and we’re delighted to be partnering with Prinova.”
Hofseth BioCare’s commitment to sustainability and zero waste has been recognised with Friend of the Sea Certification. Its entire product range is also non-GMO and free from antibiotics, solvents and chemicals.
Prinova Europe says it is already working on concepts to showcase the benefits of HBC’s products for beauty from within, exercise recovery & energy, cardiovascular support and bone health applications.
HBC also offers easily absorbed bioactive peptides derived from proprietary enzymatic technology. It is developing these into healthcare products for the treatment of iron-deficiency anaemia, Irritable Bowel Syndrome and sarcopenia.